维健医药递表港交所 华泰国际为其独家保荐人

Core Insights - The company, Weijian Pharmaceutical, has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as its sole sponsor [1] - The company holds the largest number of commercialized original drugs for kidney diseases among Chinese pharmaceutical enterprises, establishing a leading position in the relevant treatment field [1] Group 1: Product Portfolio and Market Potential - The company has developed a diverse and differentiated product portfolio, covering over 20 commercialized drugs and one candidate drug in development, addressing kidney and blood diseases, as well as extending to respiratory, skin diseases, and rare diseases [1] - The core therapeutic areas, chronic kidney disease (CKD) and blood diseases, have a large patient population and significant market potential, with the CKD drug market in China expected to grow at a compound annual growth rate (CAGR) of 11.4%, reaching RMB 82.5 billion by 2035 [1] Group 2: Strategic Partnerships and Operations - The company has established CSO partnerships with global pharmaceutical companies such as Merz Pharma and Shionogi, successfully introducing well-known original products like Kangruibao, Fulushi, and Dafi into the Chinese market [1] - The company operates an efficient collaborative system for drug development, production, and commercialization, with a production base of approximately 43,000 square meters in Zhangjiang Hi-Tech Park, Shanghai, encompassing production, quality control, warehousing, and logistics [2] Group 3: Sales and Marketing Capabilities - The company has a professional sales and promotion team of over 550 members, with a distribution network covering more than 30 provinces, over 300 cities, and reaching more than 10,000 hospitals and over 60,000 retail pharmacies and major e-commerce platforms [2] - An international business development team with experience from multinational companies like Takeda, AstraZeneca, and Johnson & Johnson is in place, with representatives in China, Japan, the USA, and Europe to efficiently select and introduce high-quality medical assets globally [2] Group 4: Funding Utilization - The funds raised will primarily be used to enhance business development capabilities through mergers, licensing, and CSO models; expand production facilities; improve commercialization capabilities, including expanding the sales team and marketing network; and implement AI and digital initiatives to enhance operational efficiency [2]